This review highlights the significant national burden of hypertension and metabolic syndrome in the US, emphasizing that cardiovascular risk doubles with every 20/10 mm Hg increase in blood pressure above 115/75 mm Hg.
Emphasizes early BP control in practice; leaves open targeted strategies amid US hypertension and metabolic syndrome burden.
BACKGROUND: Cardiovascular disease (CVD), which affects 79.4 million Americans, is a relentless problem that continues to grow by leaps and bounds. OBJECTIVE: To review current perspectives on hypertension and metabolic syndrome. SUMMARY: Hypertension can be considered a national burden: 1 in 3 American adults are hypertensive, lifetime risk of developing hypertension exceeds 90%, and the total direct costs related to hypertension and its complications approaches $49.3 billion. The risk of CVDs doubles for every increment of 20/10 mm of mercury increase in blood pressure (BP), starting at 115/75 mm Hg. Untreated elevated systolic BP may galvanize artery stiffness, and coronary heart disease (CHD) risk rises as systolic BP rises. Thus, emphasis on diastolic pressure as a risk assessment tool can be misleading, particularly in advanced age. CONCLUSION: Other risk factors for CHD include elevated cholesterol, low high-density lipoprotein cholesterol (HDL-C), smoking, and diabetes. The relative risk of cardiovascular death is increased in hypertensive patients with history of stroke, diabetes, and kidney disease. Finally, metabolic syndrome, consisting of obesity, low HDL-C, and elevated BP, triglycerides, and fasting glucose, affects 47 million people and increases diabetes and CVD risk.
No takes yet. Share an insight, caveat, or question.
George L. Bakris (2007) conducted a review in Hypertension and metabolic syndrome. Hypertension and metabolic syndrome was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: